Medicilon offers comprehensive and FDA/CFDA GLP-compliant bioanalysis services to support preclinical and clinical development for small molecule drugs, biologics, vaccines and biomarkers.
Large molecule drugs bioanalysis service
Highlights
Established in 2015 with many experienced scientists
Comprehensive information management
Validated Watson LIMS for sample and data management
Operation in Shanghai for global support
Capacity
Immunoassay Development and Validation of methods for quantitation of drug substances in biological matrices
Protein &Peptide &Antibody Drug Analysis
Biomarker Screening&Analysis
Immunogenicity (ADA)
Vaccine
State-of-the-Art Equipment
MSD Sector Imager 6000
MoleculeDevices M2/M4/M5 reader
UV 2600 spectrometer
BioTek ELx405 Select
Hamilton workstation
Large molecule bioanalysis method development & Validation
Development,Transfer, Optimization and Validation of Ligand binding Assay methods for quantitation of drug substances in biological matrices
Dozens of bioanalysis methds related to Adalimumab, Bevacizumab, Trastuzumab, Pertuzumab and Antibody Drug Conjugate(ADC) were validated and available for use
Quick validation to support potential studies
Protein&Antibody& Peptide Drug Analysis
Preclinical and Clinical studies conducted in any countries around the world